ALC

Alcon
D

ALC

Arincen77/100B

Alcon company profile

CEO
David J. Endicott
Employees
25,000
Headquarters
Chemin de Blandonnet 8, Geneva, GE 1214, CH
Sector
Healthcare
Industry
Medical - Specialties
IPO date
9 Apr 2019
Stock exchange
NYSE
ISIN
CH0432492467

Website:alcon.com

About the company

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Employees

Alcon had about 25,000 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 0.0% more than a year before.

Employees Change on the year
Fiscal yearEmployeesChange on the yearRevenue per employeeNet income per employee
FY202525,0000.00%416.04K USD39.20K USD
FY202425,0000.00%396.44K USD40.72K USD
FY202325,0000.00%378.20K USD38.96K USD
FY202225,000+4.17%348.68K USD13.40K USD
FY202124,000+4.35%345.46K USD15.67K USD
FY202023,000+3.87%297.09K USD-23.09K USD
FY201922,142+8.64%339.08K USD-29.63K USD
FY201120,381+6.54%——
FY201019,130+24.22%——
FY200915,400+6.21%——
FY200814,500+7.41%——
FY200613,500+6.30%——
FY200512,700+4.10%——
FY200512,200+2.52%——
FY200411,900+0.85%——
FY200311,800———

Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.

Who owns Alcon

Institutions such as funds, banks and insurers held 49.4% of Alcon's shares on 30 June 2026, 671 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.

Institutions 49.4%Other shareholders 50.6%

Common questions about Alcon

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.